Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) experienced a nearly 8% increase in stock price, reaching HKD 3.4, with a trading volume of HKD 5.8183 million, following the release of its interim results for the six months ending June 30, 2025 [1] Financial Performance - Other income for the company was RMB 10.542 million, representing a year-on-year decrease of 69.96% [1] - The loss attributable to shareholders was RMB 120 million, which narrowed by 42.96% year-on-year [1] - Basic loss per share was RMB 0.27 [1] Product Development - The company's core product, HTD1801, is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system [1] - HTD1801 is currently under global development for the treatment of CKM-related diseases, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1]
君圣泰医药-B涨近8% 上半年亏损同比收窄42.96%